Valuation models
price $149.52 · as of Nov 2, 2026
DCF · Perpetuity growth · 5yused141.09 – 259.09183.7119% undervaluedDCF · Perpetuity growth · 10y148.25 – 267.50191.3822% undervaluedDCF · EBITDA exit · 5y179.36 – 196.88187.8820% undervaluedDCF · EBITDA exit · 10y179.21 – 212.20194.9123% undervaluedP/E · peers120.33 – 280.27139.028% overvaluedP/E · own history77.46 – 106.5190.6165% overvaluedPEG—22.76557% overvaluedEV/EBITDA · peers174.75 – 348.26179.7717% undervaluedEV/Revenue · peers180.48 – 226.11190.8922% undervaluedEarnings power value34.09 – 62.5645.10232% overvaluedDividend discount56.99 – 182.0690.6365% overvaluedWall St. consensus target—170.0012% belowCost of capital (WACC)—6.60%—
DCF · Perpetuity growth · 5y leads for a mature, steady company — positive operating income and three years of positive free cash flow. How the headline model is chosen.
Model value · DCF · Perpetuity growth · 5y
183.71
Merck closed at $149.52 — undervalued by 19% vs model.
141.09the model's range259.09
DCF · Perpetuity growth · 5y leads for a mature, steady company — positive operating income and three years of positive free cash flow. From a five-year discounted cash flow.
Other models
22.76 – 194.91
Wall St. target
170.00 12% below
Below model, 1y
26 of 31 days
How it is valued
Valued asMature & stable
Low/slowing growth (~4% recent)High profitability (28% net margin)Pays dividendsHighly cyclical earnings
Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; how each model works is in the manual.